Mean differences (95% CI) in spirometry, oscillometry, type 2 inflammation and asthma control pre-benralizumab versus post-benralizumab
| Mean difference (95% CI) | |
| FEV1 (mL) | 230 (88, 373)** |
| FEV1 (%) | 8.8 (3.7, 13.8)** |
| FEF25–75 (L/s) | 0.156 (−0.064, 0.377) |
| FEF25–75 (%) | 4.9 (−2.1, 11.9) |
| FVC (mL) | 248 (102, 394)** |
| FVC (%) | 8.4 (4.1, 12.6)*** |
| FEV1/FVC | 1.4 (−1.3, 4.1) |
| R5 (kPa/L/s) | −0.03 (−0.10, 0.03) |
| R5 (%) | −12.0 (−30.5, 6.5) |
| R20 (kPa/L/s) | −0.02 (−0.06, 0.01) |
| R5–R20 (kPa/L/s) | −0.01 (−0.06, 0.04) |
| X5 (kPa/L/s) | 0.05 (−0.01, 0.11) |
| AX (kPa/L) | −0.40 (−1.09, 2.97) |
| Fres (Hz) | −0.50 (−3.22, 2.21) |
| FeNO (ppb) | 0 (−11, 11) |
| PBE (cells/µL) | −430 (−584, to −277)*** |
| ACQ | −1.2 (−1.8, −0.6)*** |
**p<0.01, ***p<0.001.
ACQ, Asthma Control Questionnaire; AX, reactance area; FEF25−75, forced expiratory flow rate between 25% and 75% of forced vital capacity; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; PBE, peripheral blood eosinophils.